Amylin maintained by Merrill Lynch at neutral

Amylin Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Thomas McGahren at neutral. Merrill noted that the company's sales of its diabetes drug Byetta are on track but it is still early in the launch. San Diego-based Amylin develops drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. The company has collaboration agreements with Eli Lilly & Co. and Alkermes Inc. Amylin shares Monday added 11 cents, or 0.51%, to $21.89 on volume of 2.63 million shares versus the three-month running average of 3.69 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.